Compare · DNTH vs NVO
DNTH vs NVO
Side-by-side comparison of Dianthus Therapeutics Inc. (DNTH) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DNTH and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 34.4x DNTH ($6.27B).
- DNTH has been more active in the news (16 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 14 for DNTH).
- Company
- Dianthus Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $6.27B
- $215.46B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 16
- 9
- Recent ratings
- 14
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DNTH
- Director Read Simon sold $326,554 worth of shares (2,778 units at $117.55) as part of a pre-agreed trading plan and exercised 2,778 shares at a strike of $18.36 (SEC Form 4)
- SVP, General Counsel and Sec. Veness Adam M exercised 15,000 shares at a strike of $18.17 (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Dianthus Therapeutics Inc.
- Director Mcgeorge Anne exercised 7,750 shares at a strike of $12.52 and sold $844,822 worth of shares (7,750 units at $109.01) as part of a pre-agreed trading plan (SEC Form 4)
- Director Read Simon exercised 2,777 shares at a strike of $18.36 and sold $304,232 worth of shares (2,777 units at $109.55) as part of a pre-agreed trading plan (SEC Form 4)
- SVP, General Counsel and Sec. Veness Adam M sold $2,208,833 worth of shares (20,000 units at $110.44) as part of a pre-agreed trading plan and exercised 20,000 shares at a strike of $17.88 (SEC Form 4)
- SEC Form 144 filed by Dianthus Therapeutics Inc.
- Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
- CEO AND PRESIDENT Garcia Marino exercised 166,000 shares at a strike of $8.44 and sold $17,945,451 worth of shares (166,000 units at $108.11) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Dianthus Therapeutics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S